ArticleBiomedicines2022

Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group.

Maddalena Benetton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.